The Gel That Lost Its Shape

An Essay on Polycystic Kidney Disease, Polycystic Liver Disease, and the Water in Every Cyst

This essay began with a note from a subscriber describing cysts throughout her liver and kidneys and the hopelessness of what she had been offered. The condition is called polycystic kidney disease. The medical presentation treats it as settled: inherited, progressive, incurable, managed with pharmaceuticals until the kidneys fail and the dialysis chair arrives. It is less settled than it looks.

The essay works in two registers. Mainstream nephrology’s vocabulary (polycystin-1, autosomal dominant, the drug the regulator approved) appears in attribution and quotation. The terrain paradigm (structured water, gel collapse, cleansing) operates in the author’s own voice. The shifts are intentional.

---

The Hundred-Year Count

Autosomal dominant polycystic kidney disease has been running at the same frequency in the human population since before anyone was looking for a gene.

Matthew Lanktree and colleagues sequenced two large population databases in 2018 and found the inherited variant at a rate of 9.3 per 10,000, roughly one person in a thousand.¹ Ole Dalgaard tracked 284 patients and more than a thousand family members through Copenhagen clinics in 1957 and found the condition at approximately the same rate.² Twentieth-century autopsy series in the United States documented the pattern at comparable rates decades before the gene said to cause it was identified.³

The frequency has not changed in the window during which human beings have been systematically counted. It did not require the discovery of a gene to be present. It did not require the invention of a drug to be visible. It appeared in the dead at a consistent rate under German biochemistry in 1910 and under American pathology in 1947 and under Danish pedigree analysis in the 1950s and under the sequencing registries of the 2010s.

What has also not changed is when the condition appears. The mean age at diagnosis is around 43 years. The mean age at kidney failure is approximately 57 years for carriers of PKD1 variants and between 68 and 79 for carriers of PKD2 variants. The condition is almost never diagnosed in childhood. The sequence is present from conception; the clinical disease appears four to six decades later. What fills that gap is a question the inherited-defect model has to answer, and the answers it offers lean on variable penetrance and modifier genes that have not been identified.

What was found in 1994 was not the condition. The condition was already there. What was found was a gene the researchers could associate with it. The association has been powerful enough to organize the entire clinical response for thirty years. The stability of the counts does not demolish the inheritance claim; shared family terrain also produces stable counts. The question is what the association actually explains, and the mechanism tests are where that question gets answered.

Essay PDF Download (Free Subscribers)

Audio Deep Dive (Paid Subscribers Only)

Support This Work

The essays are free and will stay free. What paid subscribers get is the library that surrounds them: the full digital book catalogue, audio deep dives, archived, and embedded in each essay, and the Questions for Your Doctor, Before You Consent, and Package Insert series. Platinum Supporters also receive the digital edition of every paperback on the day it’s published.

Whichever tier suits, thank you for being here. If you’d like to become a paid subscriber, upgrade a tier, or gift a subscription to someone who might value the work, the options are below.

What Was Found in 1994

The European Polycystic Kidney Disease Consortium published its finding in Cell in June 1994.⁴ A stretch of DNA on chromosome 16 was shown to carry the instructions for a large protein the researchers named polycystin-1. Toshio Mochizuki and colleagues identified a partner protein, polycystin-2, two years later.⁵ The two proteins work together as a complex.

Picture a kidney tubule as a thin pipe lined with cells. Each cell has a tiny hair-like projection called a primary cilium, extending into the fluid passing through. On that cilium sits the polycystin complex. The model held together like this. The complex senses the fluid flow. The sensing opens a channel. Calcium flows into the cell. The calcium keeps the cell’s internal chemistry in balance. The balance keeps the cell behaving the way a mature kidney cell should. If one polycystin is defective, the sensing fails. A messenger chemical called cyclic AMP builds up. The cell forgets which side faces the blood and which side faces the lumen, and starts pumping salt and water out the wrong side, into the tubule. The tubule swells. Over time it balloons into a cyst.

The architecture is impressive. Each step rests on experimental work. The problem is that the architecture does not survive its own foundational tests.

The Mayo Clinic maintains a database of every variant identified in these two genes that it classifies as disease-causing. The current count is over 1,500 distinct variants in PKD1 and more than 200 in PKD2.⁶ No single variant accounts for more than two percent of the patient population. The variants are overwhelmingly private, meaning each affected family tends to carry its own distinct sequence.

The flow-sensing step at the top of the cascade did not survive direct measurement. In 2016, Markus Delling and David Clapham published direct electrical recordings taken from the primary cilium itself. The title of their paper was declarative: “Primary cilia are not calcium-responsive mechanosensors.”⁷ Fluid flowing past the cilium produced no calcium signal, in any of the five tissue types they examined. The paper acknowledged, in its own words, that the Ca²⁺-responsive mechanosensor hypothesis for primary cilia had been used to explain a large range of biological responses, including the progression of polycystic kidney disease. In the same year, Peter Shen and colleagues at Utah used cryo-electron microscopy to resolve polycystin-2’s three-dimensional structure at near-atomic resolution.⁸ Two years later, DeCaen and colleagues at Northwestern, working on the same channel’s electrical function, stated plainly that they had been unable to reproduce several published reports of polycystin-2 activation and acknowledged that the basic biophysical properties of the channel remained disputed within the field itself.³⁶ The protein that was supposed to carry the signal still could not be reliably shown to carry it.

The second-hit hypothesis was invented in 1996 to resolve a different problem.⁹ Everyone with the condition inherits one defective copy of the gene and one working copy. Yet only one to five percent of the kidney’s filtering units ever becomes cystic. The hypothesis said: a cyst forms only when a cell happens, during ordinary cell division, to acquire a mutation that knocks out its second (working) copy as well. The inherited mutation alone, the researchers conceded, was not enough.

The hypothesis has since been progressively validated by sequencing. Tan and colleagues at Yale used whole-exome sequencing on 83 cysts from nine patients in 2018 and found second-hit alterations in roughly ninety percent.¹⁰ Rennert and colleagues at Weill Cornell applied whole-genome sequencing to 90 cysts from 24 patients in 2021 and found them in ninety-three percent.¹¹ Each generation of technology has produced higher detection rates in microdissected cyst epithelium. The essay does not contest the finding. What it contests is what the finding means. A second alteration being present in a cell does not establish that the alteration caused the cell to form the cyst. It establishes only that the cell carries it. Whether the alteration is upstream of the cyst, downstream of it as a consequence of the metabolic stress the cells were under while the cyst formed, or coincident with it as a marker of the terrain in which both appear, is a question the sequencing data cannot answer. The second-hit framework presumes the first interpretation. The data is equally consistent with the other two.

Within a single family, when multiple members carry the same inherited variant, the age at which their kidneys fail varies substantially. Siblings sharing the variant differ, on average, by 6.9 years.¹² Among identical twins, who share not just the variant but every other gene, no pair reported in the literature has differed by more than six years at kidney failure. Among ordinary siblings carrying the same variant, differences greater than twenty-three years have been documented. The variant is identical. The lived outcome is not. Something other than the inherited variant determines when the kidney fails.

Between ten and twenty-five percent of patients who present with the condition have no family history of it at all.¹³ The standard explanations are that the variant arose fresh in the patient’s own DNA (what geneticists call a de novo mutation) or that one parent carries it in some cells but not others. Where parents have been tested, fresh variants are confirmed in only six to eight percent of cases. The rest are explanations by default. In a further ten to fifteen percent of patients, comprehensive genetic screening finds no variant at all. They have the condition, visible on imaging, with no known genetic cause for it.

The gene is real. The variants are real. The chain between the variant and the cyst is where the model breaks. The sensing step is contradicted by direct recordings. The channel function has not been measured. The second-hit requirement has had to be chased by progressively deeper sequencing. The within-family variability has been assigned to factors medicine does not understand. What remains is association. The gene is real. The association is real. The mechanism that would turn association into causation is not. If the mechanism will not stand up on its own evidence, the next question is whether anything else produces the same pathology. Something does.

The Same Pathology, Different Label

Lithium has been used as a mood stabilizer since the 1960s. By 2000, Glen Markowitz and colleagues had assembled biopsy evidence from long-term lithium users describing “a progressive combined glomerular and tubulointerstitial nephropathy,” damage to both the filtering apparatus and the surrounding drainage tissue.¹⁴ In 2003, Marie-Thérèse Farres and colleagues scanned sixteen chronic lithium patients with MRI. All sixteen had bilateral renal microcysts measuring one to two millimeters.¹⁵ The clinical literature attributes cystic changes to lithium in a third to two-thirds of long-term users.

The mechanism as mainstream nephrology describes it: lithium enters the kidney’s collecting ducts through sodium channels. Inside the cell, it inhibits a specific enzyme that normally restrains cell growth. A growth-signaling protein called β-catenin accumulates in the nucleus. The cell starts dividing when it should not. The newly divided cells begin pumping fluid into the tubule the way defective PKD cells do. The tubule swells. A microcyst forms.

The reader will recognize the architecture. It is the architecture ADPKD is said to express. The downstream cellular cascade is indistinguishable: loss of orientation in the epithelium, elevated cyclic AMP, chloride-driven fluid secretion, luminal distension. The two conditions produce the same cysts in the same parts of the kidney. One is classified as acquired toxic nephropathy. The other is classified as a hereditary disease. The asymmetry travels in the label, not in the pathology.

Cadmium, a heavy metal present in cigarette smoke and industrial pollution, produces cystic degeneration of the kidney’s filtering tubules.¹⁶ Aristolochic acid, found in certain Chinese herbal preparations, binds directly to the DNA of tubular cells and produces its own form of cystic tubular change. The calcineurin inhibitors used after organ transplants, cyclosporine and tacrolimus, produce striped scarring and microcystic dilation.¹⁷

The clearest demonstration comes from dialysis itself. In 1977, Michael Dunnill and colleagues examined thirty hemodialysis patients at autopsy and found that nearly half had developed cysts in kidneys that had been previously normal.¹⁸ The follow-up literature traced out the dose-response curve. Among patients not yet on dialysis, cystic prevalence runs seven to twenty-two percent. By three to five years of dialysis, forty to sixty percent. By five to ten years, over ninety percent. Among affected patients, between five and nineteen percent go on to develop kidney cancer within the cysts. A Japanese review from 2000 captures the mainstream position in a single sentence: “The etiology of ACDK is unclear.” The treatment manufactures the condition in essentially everyone who stays on it long enough, and the cause is officially unknown.

In the lithium case, the cadmium case, the dialysis case, the cellular cascade is driven by an exogenous agent medicine can name. In the ADPKD case, the identical cascade is driven by an inherited variant. The label changes with the presence or absence of a named chemical. The pathology does not.

What the Cells Are Actually Doing

To see what the toxic drivers and the inherited variants have in common, follow the water.

In 1962, Gilbert Ling proposed that the standard picture of the cell was wrong at its foundation.¹⁹ The standard picture holds that the cell is a bag of liquid water enclosed by a greasy membrane, with molecular pumps built into the membrane that use ATP to keep different concentrations of sodium and potassium inside and outside the cell. Ling did the arithmetic. The sodium-potassium pump, as described, would require fifteen to thirty times more energy to run than the cell is capable of producing. The pump as pictured could not run on the fuel the cell has to burn.

Ling proposed a different account. The water inside a cell is not liquid at all. It exists in a structured state, arranged in layers around the proteins and minerals, more like a crystal than a puddle. Potassium is not pumped against a gradient; it clings to specific binding sites on proteins, held in place by electrical attraction. ATP does not store energy in its phosphate bonds; it binds to the ends of proteins, unfolds them, and makes the whole structured-water arrangement possible. Mainstream biophysics rejected the account. Ling continued to publish into his nineties.

In the 2000s, Gerald Pollack and colleagues at the University of Washington documented something unexpected. When water comes into contact with water-attracting surfaces, a zone of water extending for a fraction of a millimeter adjacent to the surface behaves very differently from ordinary bulk water. Dissolved substances, suspended particles, even small proteins, get pushed out of this zone.²⁰ The zone itself has a layered structure, carries a net negative electrical charge, and takes a six-sided lattice form, like a honeycomb seen from above. Pollack called it EZ water, short for “exclusion zone.” The hallmark of the fourth phase is that it forms a gel. The water is held in place by its structure. It will not pour out of a damaged cell the way bulk liquid water would.

Thomas Cowan has extended the structured-water framework to specific diseases.²¹ The lens of the eye is a transparent crystalline gel; disrupt the gel and the lens loses transparency, which medicine calls a cataract. The joint-cushioning sacs between bones are negatively charged gels; when the charge is lost, the pain and erosion that follow are what medicine calls osteoarthritis. The interior of every cell is itself a gel; when it collapses, the cell loses its differentiated character, falls back on a primitive sugar-burning metabolism, and grows without reference to its tissue context in the pattern medicine calls cancer.

Cowan’s published writing does not explicitly extend the framework to polycystic kidney disease. The extension that follows is my own. It is consistent with the framework Cowan, Pollack, and Ling have developed; it is not an argument from Cowan’s authority.

The kidney and the liver are the two organs through which almost everything else in the body passes. The kidney filters roughly 180 liters of blood plasma per day. The liver processes every substance absorbed from the gut and every chemical the body is working to eliminate. These are, by function, the body’s primary cleansing organs. They are also, by composition, among its most water-rich organs. The tubular cells of the kidney and the hepatocyte cords of the liver are tissues organized around high-volume fluid handling, which means they are tissues in which the structured-water gel must be maintained with particular precision for the organ to work at all.

The kidney has a further, specifically electrical role. Every fluid in the body is a colloidal suspension held together by a small negative surface charge, called zeta potential, that keeps the suspended particles from clumping. The kidneys’ job is to excrete the positively charged ions that would otherwise strip that charge from the blood. The kidney is not merely a filter. It is the organ of charge maintenance. When it fails at that job, the fluids it works in begin to stagnate. The full electrical account appears in the companion essay What Is Zeta Potential?; what matters here is that the kidney is tasked with maintaining the exact parameter whose local collapse produces cysts.

What Is Zeta Potential?

What happens when the gel fails in a small patch of tissue? The proteins that organize the arrangement lose their functional configuration. The tubule cells can no longer tell which side faces the blood and which side faces the fluid passing through, and they lose the orientation that keeps the tubule the right diameter. The water that was held structured inside the cells falls out of structure and reverts to ordinary liquid water. It collects locally as free fluid. The surrounding tissue, no longer part of a coherent gel, encapsulates the free fluid. What appears on an ultrasound is a fluid-filled sac. What medicine calls a cyst is a localized collapse of the gel. The charge has fallen and the water has pooled. The pooling is the cyst.

The framework has explanatory reach the genetic model does not, and it addresses something a careful reader will have noticed about the hundred-year count. The frequency of the sequence variations that mainstream nephrology calls PKD1 and PKD2 variants has not changed, and under the terrain framework it would not be expected to. These sequence readings travel through pedigrees because families share more than DNA. Families share the water in the taps, the food on the table, the air in the house, the dental work in the mouths, the vaccination schedule administered to the children, the pharmaceuticals passed down as medical custom. What tracks through a family tree as a shared variant also tracks as a shared terrain, over generations.

The variant frequency stays stable because what is being counted is a sequence reading. The disease burden around the counted population tells a different story. Acquired cystic conditions have appeared in direct proportion to the toxic burden medicine has imposed: the ninety-plus percent of long-term dialysis patients developing cystic kidney disease, the lithium microcysts, the cadmium nephropathy, the calcineurin-driven microcystic dilation. These are not inherited. They are produced in people whose kidneys would otherwise have remained intact, by substances medicine can name. The anatomical scale differs: the acquired microcysts are smaller than the progressive cysts of ADPKD, and the dialysis-induced cystic disease emerges in kidneys already failing from other causes. What is shared is not the gross endpoint but the cellular cascade. The cells doing the gel-collapse in those patients are responding to the same drivers that collapse the gel in the patients labeled with ADPKD. Only the second group gets classified by its cause.

The simplest reading of this clustering does not require the sequence to do any causal work at all. The mechanism tests have failed to establish that polycystin variants cause cysts, and the association between the variants and the condition is the only documented link left standing. Association is what shared family terrain already produces. The sequence found in affected families, under this reading, is a passenger: a marker that travels with the same families who share the exposures, the water, the dental history, the vaccination schedule, the generational pharmaceutical custom. Nothing in the sequence needs to be doing anything for the clustering to appear.

For readers not yet ready to detach the sequence from the condition, the mainstream literature itself offers a harder question than it usually acknowledges. Toxic substances damage DNA. This is well-established: ionizing radiation, benzene, formaldehyde, polycyclic aromatic hydrocarbons, cadmium, arsenic, and a long list of pharmaceuticals including chemotherapy agents developed specifically as mutagens all produce measurable sequence changes. When the exposure reaches germ cells or a developing fetus, the sequence changes pass to the next generation. Michael Skinner and colleagues at Washington State University have documented a second inheritance vector: pregnant rats exposed to the fungicide vinclozolin produced descendants with elevated rates of adult-onset kidney disease, prostate disease, tumor formation, and immune dysregulation, running through at least four generations.³⁵ The chemical annotation sitting on top of the DNA, which tells the cell which parts to read and which to ignore, had been reconfigured by the ancestor’s exposure and passed through sperm and egg. Industry-funded replication attempts using different protocols have not fully reproduced the original vinclozolin finding; Skinner’s lab has extended the core result to DDT, jet fuel, BPA, dioxin, and other compounds across two decades of continued work, and the broader field of transgenerational epigenetic inheritance is now mainstream. Even inside the mainstream framework, then, the scatter of Mayo-cataloged alterations across the length of PKD1, with no single alteration accounting for more than two percent of patients and each family carrying its own distinct version, looks more like inherited damage from a diversity of ancestral exposures than like a single inherited design flaw replicated down a lineage.

The condition appears predominantly in the two organs that handle the most toxic throughput because those are the organs in which the gel is most heavily taxed. The sequence found in affected families is a marker that tracks with the terrain those families have been living in, not an instruction set that programs the kidney to fail.

The framework proposes a mechanism. It does not prove a cure. No published peer-reviewed case report documents the anatomical reversal of ADPKD or PLD through terrain-based intervention. The honest ground is that the gel-collapse framework is a hypothesis supported by its coherence with observed phenomena and by the failure of the genetic model’s own foundational tests, not by randomized evidence of reversal. What the framework explains, beyond the particular case of PKD, is why cysts show up as often as they do in as many places as they do.

The Pattern Across Organs

Cystic conditions are not rare in medicine. They are a daily reading in radiology.

Simple renal cysts appear in ten to twelve percent of the general population and in thirty to fifty percent of adults over sixty. Simple hepatic cysts appear in five to eighteen percent of imaging series. Pancreatic cysts appear in two to three percent of routine CT scans and up to twenty percent of high-resolution MRIs in older patients. Thyroid nodules with cystic degeneration appear in fifty to sixty-five percent of adults on ultrasound. Pineal cysts in the brain appear in up to forty percent on high-resolution imaging. Fibrocystic breast changes affect roughly half of all women across their lifetime. Baker’s cysts behind the knee appear in five to nineteen percent of knee MRIs. Ovarian functional cysts appear in nearly all ovulating women at some point. Ganglion cysts account for fifty to seventy percent of all soft-tissue lumps on the hand and wrist. Each organ has its own prevalence and its own mainstream story. (The specific prevalence figures warrant primary-source verification.)

Mainstream medicine does not have a unifying account of cystic conditions. The nearest attempt is the ciliopathy framework, which groups together conditions involving the primary cilium (the hair-like projection described earlier): polycystic kidney disease, polycystic liver disease, nephronophthisis, Bardet-Biedl syndrome.²² The framework does not extend to cystic conditions in organs without primary cilia. The Baker’s cyst is not a ciliopathy. The thyroid nodule is not a ciliopathy. The pineal cyst is not a ciliopathy. For each of these, mainstream pathology provides a local explanation, often with the qualifier that the underlying trigger is unknown. Pineal cysts are “entirely idiopathic.” Fibrocystic breast change is “a physiological variant whose cellular basis is unknown.” Ganglion cysts show “underlying triggers unknown.” The cross-organ pattern is being described one tissue at a time, with the common thread of unexplainedness running through all of them.

Under the gel-collapse framework, each of these conditions appears in a tissue that normally holds water in a structured gel. The kidney tubule, the liver cord, the pancreatic duct lining, the thyroid follicle, the pineal gland, the breast lobule, the knee bursa, the ovarian follicle, the periarticular synovium. These are high-water-content tissues organized around managed fluid compartments. When the gel managing those compartments fails locally, free fluid collects locally. The condition takes the name of the organ in which the collection appears, and the diagnostic label is then treated as explanatory.

The subscriber whose letter prompted this essay has cysts in both her kidneys and her liver. She has been given a label and a prognosis for a rare inherited condition. In the pattern laid out here, she is one instance of a very common thing happening in two organs that happen to be her body’s most heavily worked.

The renaming of what used to be called polycystic ovary syndrome is the most instructive case. In May 2026, a global consensus process led by Helena Teede renamed the condition polyendocrine metabolic syndrome (PMOS) on the grounds that it does not involve pathological ovarian cysts.²³ The follicles seen on ultrasound in these patients are arrested at an immature stage; they are not true cysts. The Endocrine Society position is that “there is no increase in abnormal ovarian cysts in the condition.” The condition kept its name for forty years. The follicles were being counted as cysts for forty years. The reclassification is the kind of institutional admission that gets made quietly after the drug protocols have been well established.

The Pipeline

Having told the patient the condition is inherited and incurable, medicine then offers a treatment.

Tolvaptan is the pharmaceutical approved for ADPKD. The body uses a hormone called vasopressin to regulate water retention. Vasopressin binds to receptors in the kidney’s collecting ducts and triggers water reabsorption into the blood. In PKD, that same signaling pathway also drives fluid secretion into the cysts, which is what makes the cysts grow. Tolvaptan blocks the receptor. The signal that was feeding the cysts is interrupted. The FDA approved the drug for ADPKD in April 2018 under the brand name Jynarque, following the European approval of the same drug (Jinarc) in May 2015.²⁴ ²⁵

The pivotal trial, TEMPO 3:4, enrolled 1,445 patients and followed them for three years.²⁶ In the treatment arm, total kidney volume grew 2.8 percent per year. In the placebo arm, 5.5 percent per year. The standard clinical measure of kidney function, the estimated glomerular filtration rate (how fast the kidneys can filter waste out of the blood), declined at approximately 2.72 units per year on treatment and 3.70 on placebo. The follow-up trial REPRISE confirmed a similar effect in more advanced patients.²⁷ Across both trials, roughly fifteen to twenty-three percent of patients discontinued the drug for adverse events.

The treatment carries a boxed warning for serious and potentially fatal liver injury, the FDA’s strongest safety signal. Blood markers of liver cell damage exceeded three times normal in 4 to 5 percent of treated patients compared with 1 percent of placebo.²⁸ Three cases met what is called Hy’s Law criteria during drug development, the clinical signal regulators use to flag drugs capable of causing fatal liver failure. Dispensing is restricted under a Risk Evaluation and Mitigation Strategy requiring monthly liver blood tests for the first eighteen months and quarterly tests thereafter, for as long as the patient remains on the drug. Treatment is intended to be indefinite.

The drug produces five to seven liters of urine per day on the standard dose. The reported adverse reactions include constant thirst, excessive urination, nighttime urination, elevated blood sodium, elevated uric acid, gout, and dehydration.

The drug slows the progression of a condition it does not cure. The preservation of 1.27 filtration units per year, over an eighteen- to twenty-two-year disease course, extends time to dialysis by roughly six and a half years in modeled analyses. A 2013 cost-effectiveness analysis by Erickson, Chertow, and Goldhaber-Fiebert calculated the drug’s cost at $744,100 for every additional quality-adjusted life year it bought a patient.²⁹ (A quality-adjusted life year is the measure health economists use: a year lived in full health counts as 1.0, and a year lived with substantial illness counts as something less.) Standard thresholds for cost-effective interventions in the United States run between $50,000 and $100,000 per quality-adjusted year. The authors concluded that the drug would meet conventional thresholds only if its price fell by approximately eighty percent. The price has not been reduced. The 2018 US launch cost was approximately $170,000 per year; by 2025, roughly $280,000.

What waits downstream of the drug is the dialysis industry. The Medicare End-Stage Renal Disease program, established under the Social Security Amendments of 1972, covers all US citizens with permanent kidney failure regardless of age or income. Medicare spending on ESRD was $55.3 billion in 2023.³⁰ The outpatient dialysis market is dominated by DaVita (approximately 36 percent of the US market) and Fresenius (approximately 38 percent); their combined share rose from 59 percent in 2005 to 77 percent by 2019.

In April 2018, Salveen Richter and colleagues at Goldman Sachs circulated an equity research report titled “The Genome Revolution.” It raised a question that has since become familiar: “Is curing patients a sustainable business model?”³¹ The example given was Gilead Sciences’ direct-acting antivirals for hepatitis C, which the industry marketed as a cure and which, by that framing, had depleted the manufacturer’s own patient population: US sales peaked at $12.5 billion in 2015 and have fallen every year since. What the market treats as a cure produces a terminal revenue curve. A chronic management therapy produces an annuity.

The structure of ADPKD care, from early diagnosis through tolvaptan through dialysis through transplantation and lifelong anti-rejection medication, is a decades-long annuity. The condition does not need to be cured for the business model to function. The condition does need to remain uncurable for the business model to function. The investment thesis depends on the condition staying what it has been described to be for the last thirty years: inherited, progressive, unresolvable.

What Follows

What should a person who has been handed this diagnosis actually do?

The gel-collapse framework is a mechanism argument supported by its coherence with observed phenomena. It is not supported by randomized clinical evidence of PKD reversal; no such evidence exists. What I can describe is what the terrain tradition does for people with cystic conditions and compromised cleansing organs, and what the mainstream data suggest about the drivers worth addressing.

The terrain tradition is not a protocol. It is a way of thinking about the body. In the formulations of John Tilden, Herbert Shelton, Henry Bieler, and Ulric Williams, the body is a self-regulating organism that heals when the conditions for healing are permitted.³² The conditions include removal of the exogenous drivers producing the pathology, provision of the nutritive substrates the organ needs for repair, maintenance of the eliminative pathways through which toxins are cleared, and sufficient rest for the restorative processes to work.

For a kidney and liver carrying cystic burden, the removable drivers worth examining are specific.

Pharmaceuticals known to produce cystic kidney changes should be reviewed with the prescribing clinician: lithium, calcineurin inhibitors, long-term NSAIDs, long-term combination analgesics. Nothing in a prescribed regimen should be altered without consultation.

The injection schedule is where the primary cause hierarchy most directly meets the organs this essay is about. Charles Richet was awarded the 1913 Nobel Prize for demonstrating that injection of foreign proteins creates sensitization, a condition in which the body responds more and more violently to each subsequent injection of the same material, and in his animal experiments the sensitization produced inflammatory damage at the body’s filtering sites. Richet’s finding was foundational enough to earn the highest prize in medicine. It was then expunged from the explanatory framework of twentieth-century medicine with such efficiency that few practicing clinicians today could describe what Richet actually demonstrated.

The kidney and liver are the organs doing the clearance of whatever the injections deliver. The lipid nanoparticles, the aluminum adjuvants, the modified mRNA sequences, the polysorbate carriers: these are substances the kidney and liver are tasked with handling. The cumulative schedule over a modern lifetime, from the childhood series to the adult boosters, passes through those two organs.

Aluminum, the standard vaccine adjuvant, deserves separate attention. It carries a triple positive charge, which makes it, by the Schulze-Hardy rule established in the 1880s, between six hundred and fifteen hundred times more effective at collapsing the electrical stability of blood than a monovalent cation such as sodium. Municipal sewage plants use aluminum sulfate for exactly this purpose: to clump suspended organic solids so they can be removed. Ingested aluminum is largely blocked at the gut, with roughly 0.1 to 0.6 percent reaching the bloodstream. Injected aluminum enters the bloodstream directly, in bolus. The organ tasked with excreting it is the organ this essay is about. The kidney is asked, across a lifetime of injections, to clear the exact substance that destroys the colloidal stability of the blood it was built to maintain.

Joy Garner’s Control Group Survey, conducted across forty-eight states in 2019 and 2020, documented chronic disease in the vaccinated adult population at sixty percent and in the fully unvaccinated at 2.64 percent, a roughly twenty-three-to-one ratio across chronic disease generally.³⁴ Whether that ratio tracks the rate at which carriers develop symptomatic disease, or the rate of acquired cystic conditions outside the carrier population, has not been looked at.

I have not been able to find a peer-reviewed study examining whether the age at which cysts become radiologically visible in carriers tracks the childhood injection schedule. I have not found one examining whether the age at kidney failure in carriers correlates with the aggregate adult injection burden. I have not found one comparing the rate of acquired cystic kidney disease, in any of its documented forms, between populations with high and low injection exposure. The terrain framework predicts correlations in all three. The studies that would test those predictions have not been done. The absence is not an oversight. It is a choice. A question not asked is a question whose predictable answer the field has decided not to confirm.

The remaining removable drivers are environmental. Heavy metals, pesticide residues, chlorinated or fluoridated water in the diet. Dental amalgam, which continues to vent mercury vapor into the body for decades after placement. Mold exposure of the home. Electromagnetic exposure in the sleep environment.

The nutritive support that the kidney and liver require is mineral-dense, enzyme-rich, whole food. Weston Price documented fourteen traditional populations that were virtually free of the degenerative conditions afflicting the industrialized world, eating wildly different diets with a common denominator of mineral density, organ meats, and the deep nourishment of connective tissues.³³ Henry Bieler’s broth of zucchini, string beans, celery, and parsley was his clinical restorative formula for the liver. The eliminative support is simple to state and demanding to practice: daily movement, deep breathing, castor oil packs over the right upper quadrant of the abdomen (where the liver sits), and sufficient rest.

Where restoration of the blood’s colloidal charge is a specific aim, Thomas Riddick’s protocol from the late 1960s remains available: potassium citrate and potassium bicarbonate in distilled water, with removal of aluminum cookware, aluminum-containing baking powders and antacids, and aluminum-canned beverages. The McDaniel formula, developed independently in the 1970s by a Cincinnati osteopath over fifty-two years of clinical practice and still produced, is substantially the same. The full operational catalog of zeta-restoring interventions is in the companion essay already referenced.

Autosomal dominant polycystic kidney disease has not been documented to anatomically reverse under any protocol, terrain or pharmaceutical. The claim available to the terrain tradition is modest. The trajectory can be slowed. The systemic burden can be reduced. The cysts are unlikely to disappear. What changes is that the person stops being treated as a disease and starts being treated as a person whose body is doing something that can be understood and partially supported.

Closing

What the subscriber asked about was whether anything else was possible beyond what she had been offered. The answer that mainstream nephrology provides to that question is: not really. The gene is in the family. The drug is available. The dialysis is waiting. The transplant list is roughly five years long.

The answer the terrain framework provides is different. The condition is not what she has been told it is. It is the shape her body has taken under a terrain that, somewhere, cannot be sustaining the gel that holds the water in the right places. The drivers of that terrain collapse are not fully identifiable in any individual case, and the extent to which they can be reversed is not fully knowable in advance. What is knowable is that the condition occurred at the same rate in 1910 as it does today. Neither genetics nor modernity in itself is a sufficient explanation. Something older is at work.

The 1910 autopsy records do not tell us what that something is. The 1994 gene identification did not tell us either. The mechanism from variant to cyst has not held up under its own foundational tests, and the mainstream literature now openly says so, in language guarded enough that most readers never notice.

What this means for an individual person is not a protocol anyone can hand over in an essay. The body is not a mistake, the condition is not an identity, and the question has not been settled, however finished the clinical presentation claims to be.

The documents are publicly available. The autopsy counts, the variant database, the ciliary paper, the trial results, the drug pricing, the dialysis industry’s revenue, the Goldman Sachs note. Whatever word is chosen for the gap between what the documents say and what patients are told, the documents say what they say. The condition is older than the gene. The cells are a gel, and the gel is not what it was.

How to Explain It to a Six-Year-Old

Imagine Jell-O. When it sets properly, it is firm and holds its shape and wobbles when you poke it but doesn’t fall apart. If you don’t follow the recipe right, parts of the Jell-O don’t set. Those parts stay as runny water inside the firm Jell-O. The runny parts collect into little bags of water inside the shape.

Your body is made mostly of water. The water is not supposed to slosh around. It is supposed to be held in place like Jell-O, so your body can keep its shape and do its work. The two parts of your body that handle the most water every day are the kidneys and the liver. The kidneys clean your blood. The liver cleans up everything you eat.

If the recipe for the Jell-O inside those parts goes wrong, little bags of water collect inside them. Doctors call those little bags cysts. Some people are told the recipe went wrong because of something they were born with. For a long time, that was the only explanation anyone offered. The problem is that there are many things that can make the recipe go wrong, like certain medicines, or things in the water, or things in the air. The body can sometimes fix the recipe if the things that made it go wrong are taken away.

The water is still your water. The Jell-O can still be helped. The body is not making a mistake. It is doing the best it can with what it has.

Medical Disclaimer

This essay is informational, not medical advice. The paradigm it operates in, the terrain paradigm, is not the paradigm in which licensed medical practice operates. Readers considering any of the practical measures described, including Riddick’s Regimen, the McDaniel formula, castor oil packs, dietary and environmental changes, or any of the specific therapies mentioned in What Follows, should do so with their own research, their own judgment, and the involvement of a practitioner they trust. Readers currently taking pharmaceutical medications, including tolvaptan, should not alter their regimens without discussing changes with the practitioner who prescribed them. The intent of this essay is to make the gel-collapse framework legible to a reader who has not previously encountered it, and to make clear that the mechanism and its clinical consequences have been documented repeatedly, independently, and across decades. What any individual reader does with that knowledge is their own decision.

In Print

The Unbekoming library is available in paperback, printed to order through Lulu and shipped worldwide. The shelf begins with the paradigm question underneath everything else — No Virus, the isolation problem, the collapse of virology’s foundational claims, and a disease-by-disease reappraisal — and moves through the suppressed compounds mainstream medicine set aside: The DMSO Book, Chlorine Dioxide: The Forbidden Remedy, The Iodine Book, and The Hydrogen Peroxide Book. Two more recover what’s still on the kitchen shelf: Baking Soda and The Castor Oil Book. Two more recover the minerals modern soil, water, and processing quietly stripped from the diet: The Magnesium Handbook and The Boron Book. Sitting alongside these is No Contagion, co-authored with Jamie Andrews — the case against germ theory itself, catalogued through 258 failed contagion experiments.

The critique books cover what medicine, dentistry, psychiatry, and veterinary practice have become. The Unvaccinated treats the completely unvaccinated as a comparison group across twenty chapters and five appendices. Medicalized Motherhood follows a woman through 123 documented interventions from teenage pill to postpartum discharge. Drilling for Profit treats cavities, gum disease, and crooked teeth as the dietary problem they are. What Your Vet Can’t Tell You applies the same critique to pets. Escape from Psychiatry documents the fabrication of the DSM and the specific damage of every major psychiatric drug class. The Vitamin K Injection covers what happens in the first hours of a newborn’s life.

The full shelf is at lulu.com/spotlight/unbekoming. A physical book reaches the person a Substack post never will — the skeptical relative, the friend who won’t click a link but might open a book, the visitor whose eye lands on a coffee table. Buy one to keep, and one to give away.

References

1. Lanktree MB, Haghighi A, Guiard E, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. Journal of the American Society of Nephrology. 2018;29(10):2593–2600.

2. Dalgaard OZ. Bilateral polycystic disease of the kidneys: a follow-up of two hundred and eighty-four patients and their families. Acta Medica Scandinavica Supplementum. 1957;328:1–255.

3. Early autopsy prevalence of adult polycystic kidney disease: see Bell ET, Renal Diseases, 2nd ed., Lea & Febiger, Philadelphia, 1950. The specific autopsy ratio cited in the research literature (131 cases in 59,064 autopsies) warrants verification against Bell’s original text before citation.

4. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell. 1994;77(6):881–894.

5. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272(5266):1339–1342.

6. Mayo Clinic ADPKD Variant Database (PKDB). Current catalog of pathogenic variants in PKD1 and PKD2. See also the review “Genetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes,” 2023, PMC10746289.

7. Delling M, DeCaen PG, Doerner JF, Febvay S, Clapham DE. Primary cilia are not calcium-responsive mechanosensors. Nature. 2016;531(7596):656–660.

8. Shen PS, Yang X, DeCaen PG, Liu X, Bulkley D, Clapham DE, Cao E. The structure of the polycystic kidney disease channel PKD2 in lipid nanodiscs. Cell. 2016;167(3):763–773. The quoted admission on native PKD2 currents circulates in secondary research literature and should be matched against the primary source during final verification.

9. Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell. 1996;87(6):979–987.

10. Tan AY, Zhang T, Michaeel A, et al. Somatic second-hit mutations in PKD1 and PKD2 cysts: whole-exome sequencing. Journal of the American Society of Nephrology. 2018. Full bibliographic details warrant verification.

11. Rennert H, Robinson BD, Tan AY, et al. Detection of PKD1 and PKD2 somatic variants in autosomal dominant polycystic kidney cyst epithelial cells by whole-genome sequencing. Journal of the American Society of Nephrology. 2021;32(12):3114–3129.

12. Lanktree MB, et al. Intrafamilial variability of ADPKD. Kidney International Reports. 2019;4:995–1003. Twin data from a 2025 ADPKD monozygotic twin cohort analysis in Kidney International Reports complements the sibling-variability data.

13. Iliuta IA, Kalatharan V, Wang K, et al. Polycystic kidney disease without an apparent family history. Journal of the American Society of Nephrology. 2017;28(9):2768–2776.

14. Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. Journal of the American Society of Nephrology. 2000;11(8):1439–1448.

15. Farres MT, Ronco P, Saadoun D, et al. Chronic lithium nephropathy: MR imaging for diagnosis. Radiology. 2003;229(2):570–574.

16. Cadmium nephrotoxicity: Prozialeck WC, Edwards JR, Nebert DW, et al. The vascular system as a target of metal toxicity: treatment implications for arterial hypertension. Toxicology and Applied Pharmacology. 2007. Citation warrants verification.

17. Calcineurin inhibitor nephrotoxicity: Chapman JR, Nankivell BJ. Chronic calcineurin inhibitor nephrotoxicity: lest we forget. American Journal of Transplantation. 2004. Citation warrants verification.

18. Dunnill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. Journal of Clinical Pathology. 1977;30(10):868–877.

19. Ling GN. A Physical Theory of the Living State: The Association-Induction Hypothesis. Blaisdell Publishing Co., New York, 1962.

20. Zheng JM, Chin WC, Khijniak E, Khijniak E Jr, Pollack GH. Surfaces and interfacial water: evidence that hydrophilic surfaces have long-range impact. Advances in Colloid and Interface Science. 2006;127(1):19–27.

21. Cowan T. Cancer and the New Biology of Water. Chelsea Green Publishing, White River Junction, VT, 2019. See also Cowan T, Fallon Morell S, The Contagion Myth, Skyhorse, 2020.

22. Badano JL, Mitsuma N, Beales PL, Katsanis N. The ciliopathies: an emerging class of human genetic disorders. Annual Review of Genomics and Human Genetics. 2006;7:125–148.

23. Teede HJ, et al. Renaming of polycystic ovary syndrome to polyendocrine metabolic syndrome following multistep global consensus process. The Lancet. 12 May 2026. Specific citation warrants independent verification.

24. US Food and Drug Administration. Jynarque (tolvaptan) tablets, label approval NDA 204441. 23 April 2018.

25. European Medicines Agency. Jinarc (tolvaptan) authorization EMEA/H/C/002788. 27 May 2015.

26. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. The New England Journal of Medicine. 2012;367(25):2407–2418.

27. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. The New England Journal of Medicine. 2017;377(20):1930–1940.

28. Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease. Drug Safety. 2015;38(11):1103–1113.

29. Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Annals of Internal Medicine. 2013;159(6):382–389.

30. United States Renal Data System. 2025 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, NIDDK.

31. Richter S, et al. The Genome Revolution. Goldman Sachs Equity Research Report. 10 April 2018.

32. Tilden JH, Toxemia Explained, 1926 (reprint FQ Classics 2007); Shelton HM, Fasting and Sunbathing, 1934; Williams U with Bailey M, Terrain Therapy, 2022; Bieler HG, Food Is Your Best Medicine, Random House, 1965.

33. Price WA. Nutrition and Physical Degeneration. 1939. Reprint Price-Pottenger Nutrition Foundation.

34. Garner J. Control Group Survey of chronic disease rates in fully unvaccinated versus vaccinated American adults. Forty-eight state survey, 2019–2020. See also Unbekoming, The Primary Cause: An Essay on One Impost, Three Shadows, July 2026, for the full argument from the Garner data.

35. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005;308(5727):1466–1469. See also Anway MD, Leathers C, Skinner MK. Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. Endocrinology. 2006;147(12):5515–5523, documenting kidney disease persistence across F1–F4 generations.

36. Liu X, Vien T, Duan J, Sheu SH, DeCaen PG, Clapham DE. Polycystin-2 is an essential ion channel subunit in the primary cilium of the renal collecting duct epithelium. eLife. 2018;7:e33183. The paper explicitly states: “several putative polycystin-2 activators have been reported to sensitize polycystin-2 channels, but we have been unable to reproduce these results.”

The electrical dimension of the gel-collapse framework developed in Section 4 of this essay is treated in full in Unbekoming, What Is Zeta Potential? An Essay on the Charge That Organizes Living Tissue, October 2026.

The construction of hepatitis C as a viral disease, and the terms on which Gilead’s direct-acting antivirals were marketed as a cure for it, is treated in full in Unbekoming, What Is Hepatitis C? An Essay on the Virus Nobody Has Seen, the Test That Created an Epidemic, and the Drugs That Damaged the Organ They Claimed to Treat, May 2026.

Additional Sources

Lester D, Parker D. What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong. 2019.

Bailey M, Bailey S. The Final Pandemic: An Antidote to Medical Tyranny. 2023.

Pollack GH. The Fourth Phase of Water: Beyond Solid, Liquid, and Vapor. Ebner & Sons Publishers, Seattle, 2013.

Pollack GH. Cells, Gels and the Engines of Life. Ebner & Sons Publishers, Seattle, 2001.

Gober M, Bailey S, Bailey M, Lanka S. An End to Upside Down Medicine: Contagion, Viruses, and Vaccines. Waterside Productions, 2023.

Roytas D. Can You Catch a Cold? Untold History and Human Experiments. 2024.

Engelbrecht T, Köhnlein C, Bailey S, Scoglio S, Yamamoto M. Virus Mania. 3rd ed., 2021.

Cowan T. Human Heart, Cosmic Heart. Chelsea Green Publishing, 2016.

McGarey WA. The Oil That Heals: A Physician’s Successes with Castor Oil. A.R.E. Press, Virginia Beach, VA, 1993.